

Clinical significance of PSMA, TERT and PDEF in malignant tumors of the prostate

J. SITU¹, H. ZHANG¹, L. LU², K. LI¹, C. HU¹, D.-J. WANG¹

¹Department of Urology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China

²Department of Urology, the Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China

Jie Situ and Hao Zhang contributed equally to this paper

Abstract. – OBJECTIVE: To investigate the clinical significance of the expression of PSMA (prostate specific membrane antigen), TERT (telomerase reverse transcriptase), and PDEF (prostate derived Ets factor) in malignant tumors of the prostate.

PATIENTS AND METHODS: The study was conducted with paraffin slices from 33 specimens of malignant tumors of the prostate and 17 of normal tissue. We found high levels of PSMA, TERT, and PDEF protein by Western blot and immunofluorescence in the malignant tumor of the prostate. We also detected upregulation of PSMA, TERT, and PDEF mRNA in the malignant tumor of the prostate, suggesting complex regulation of these three genes in prostate cancer.

RESULTS: Variance analysis showed statistically significant differences concerning the expression of PSMA, TERT, and PDEF in malignant tumor of the prostate and normal tissues. The high expression of PSMA, TERT, and PDEF in the malignant tumor of the prostate suggests the important roles of these three genes in the occurrence and development of malignant tumors of the prostate.

CONCLUSION: PSMA, TERT, and PDEF may serve as a reference for clinical diagnosis and as potential targets for the malignant tumor of the prostate therapeutics.

Key Words:

PSMA, TERT, PDEF, Malignant tumor of the prostate, expression levels.

Introduction

The rise in morbidity and mortality of malignant tumors of the prostate in recent years make a need for identifying effective markers that enable early and accurate diagnosis and intervention^{1,2}. Despite the recent efforts, the pathogenesis of malignant tumors of the prostate is still unclear, and effective treatments are no available³. Here,

we detected the expression levels for three relevant tumor markers, PSMA (Prostate Specific Membrane Antigen), TERT (Telomerase Reverse Transcriptase) and PDEF (Prostate Derived Ets Factor) – by different techniques in malignant tumors of the prostate and normal prostate tissue. The high expression of PSMA, TERT, and PDEF in PDEF malignant tumor of the prostate at the protein and mRNA levels suggests their important roles in the development of malignant tumors of the prostate. This information can be relevant for the clinical diagnosis and treatment of prostate cancer.

Patients and Methods

Collection of Tumors

We collected 33 specimens of malignant tumors of the prostate and 17 of normal prostate tissue in our hospital. They were fixed in neutral formalin (10%) for over 48 h, embedded in paraffin, and cut into the 5 μ m slices. The Ethic Committee of the Third Affiliated Hospital approved this study.

Immunofluorescence

The tissue slices were de-waxed by dimethylbenzene several times and then dehydrated by ethanol gradient for antigen retrieval. After the slices were washed 3 times (5 min/time) with PBS (pH = 7.4), they were blocked in 10% bovine serum albumin (BSA) in a humidity chamber at 37°C for 30 min. Then, the slices were washed in phosphate-buffered saline (PBS) (pH = 7.4) once to remove excess of bovine serum albumin (BSA). Then, the primary antibody (1:70) was added into the slices and incubated in the humidity chamber at 4°C overnight. The next day, we

washed the slices three times (5 min/time) with PBS and added the fluorescent secondary antibody in the dark and incubated in the humidity chamber at 37°C for 2 h. After the slices were washed with the secondary antibody, they were sealed in glycerol for observation under the fluorescence microscope. mAb anti-β-Actin, anti-PSMA, anti-TERT, and anti-PDEF, as well as fluorescence secondary antibody, were obtained from Cell Signaling Technology (Danvers, MA, USA).

RT-PCR Detection

Two samples (50 mg) from the malignant tumor of the prostate and normal tissues were rapidly transferred to 1 mL of Trizol (Tiangen Biotech, Beijing, China) and homogenized. After 5 min at the room temperature, the homogenate was centrifuged at 12,000 × g and 4°C for 15 min. The supernatant was mixed with chloroform. After 5 min at the room temperature, the mixture was centrifuged at 12,000 × g at 4°C for 15 min. Then, the same volume of isopropanol was added to the mixture. After 10 min at the room temperature, the mixture was centrifuged at 12,000 × g and 4°C for 10 min and the pellet was collected. We mixed the pellet with 1 mL of 75% ethanol to wash the RNA. Then, it was dissolved in RNase-free water. The concentration of RNA and the ratio of OD₂₆₀/OD₂₈₀ were determined. Finally, the mRNA for PSMA, TERT, and PDEF were amplified using the primers in Table I. The products were used for RT-PCR analysis (Tiangen Biotech, Beijing, China).

Western Blot

Two tissue samples (50 mg) were collected from the malignant tumor of the prostate and normal tissues, washed in physiological saline, and homogenized with lysis buffer. Then, the homogenates were centrifuged at 12,000 × g at 4°C for

10 min, and the supernatant was centrifuged again under the same conditions, and then we collected the supernatant. The protein concentration was assayed by the BCA protein assay kit (Beyontian, Beijing, China) and the samples were preserved at -80°C. The extracts were mixed with 2X loading buffer (100 μl + 4 μl-mercaptoethanol) at a volume ratio of 1:1, the mixture was boiled in boiled water for 5 min, and then preserved in refrigerator. The separation gel and 5% stacking gel were prepared according to the molecular weight of the target protein. The homogenates were loaded on the gel, and the electrophoresis was performed under a constant voltage of 220 V until the bromophenol blue reached the bottom of the gel. The gel was then cut into pieces according to the molecular weight of the target proteins and placed into transfer buffer. The polyvinylidene fluoride (PVDF) membrane was cut into the shape of the gel and was placed into the transfer buffer after being soaked in methanol for 10 s. Next, the membrane transfer was performed at a constant voltage of 100 V. The PVDF membrane was blocked with 5% skim milk powder for 3 h at room temperature on the shaker. The membranes were incubated with the primary antibodies at 4°C overnight and then washed three times in TTBS (10 min/time). The membrane was incubated with the secondary antibody on the shaker at a room temperature for 2 h and washed three times in TTBS (10 min/time). The mixed solution of reagents A and B in the electrochemiluminescence (ECL) assay kit were added onto the PVDF membranes for complete reaction. After 1 min of color development in the dark, the mixture was put into the gel imager and photographed using dynamic calculus pattern, and the gray analysis was performed on the protein strips using Gel-Pro 4.0.

Statistical Analysis

SPSS 18.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis of results. The experimental data were presented as mean ± standard deviation (Mean ± SD). *t*-test, *p*-test, and One-Way ANOVA variance analysis were performed in-group comparisons. *p* < 0.05 suggested that the differences were statistically significant.

Results

Pathological Slices

The glands were in back to back arrangement, and the original basal cells significantly disap-

Table I. RT-PCR primer sequence of EGF and TGF-α mRNA.

Name of gene	Primer sequence
PSMA	5'-3' ACATGGAAGCCATCACAGAC 3'-5' AGACCGTTCAGCTGGATATTA
TERT	5'-3' ACCCCTCCGGTCCCCGGCCC 3'-5' GAGTTTCCGGCAGCGGCCA
PDEF	5'-3' TTGACAGCGACAAGAAGTGG 3'-5' TCACGTCGTCCTTATGCAAG
β-actin	5'-3' GAGCCGGGAAATCGTGCGT 3'-5' GGAAGGAAGGCTGGAAGATG




Figure 1. Pathological results of the normal prostatic tissues and the malignant tumor of the prostatic tissues.

appeared in the malignant tumor of the prostatic tissues (Figure 1). Compared with the slices of normal prostatic tissues, gradient vacuolization of nuclei and significantly infiltrated interstitial were identified in the malignant tumor of the prostatic tissues (Figure 1). Furthermore, we found that the nuclei were mutated and the glands were distributed irregularly, instead of the original arrangement.

Immunofluorescence of PSMA, TERT, and PDEF in Prostatic Tissues

Fluorescent expression of PSMA, TERT, and PDEF was identified in the malignant tumor of

prostatic tissues, but not in the normal tissues (Figure 2). Additionally, PSMA, TERT, and PDEF were highly expressed in the malignant tumor of the prostatic tissues. The result indicated the clinical significance of PSMA, TERT, and PDEF in malignant tumor of the prostate.

Western Blot Analysis of PSMA, TERT, and PDEF in Prostatic Tissue

To examine the protein expression of PSMA, TERT, and PDEF by a more quantitative method, we conducted Western blot analysis. The protein levels of PSMA, TERT, and PDEF were highly elevated in the malignant tumor of




Figure 2. Expression of PSMA, TERT and PDEF in the normal tissues and the malignant tumor of the prostatic tissues (×400).

the prostatic tissues, but very lowly expressed in the normal tissues (Figure 3). Each protein was elevated more than ten times in prostate tumors compared to normal prostatic tissue, supporting the strong signal observed by immunofluorescence.

mRNA Levels of PSMA, TERT, and PDEF in Prostatic Tissue

After observing the marked upregulation of PSMA, TERT, and PDEF at the protein level, we decided to analyze the expression of PSMA, TERT, and PDEF mRNA to understand how these genes are regulated. PSMA, TERT, and PDEF mRNA were significantly increased in malignant tumor of the prostatic tissues compared to the normal prostate (Figure 4). PSMA showed the highest upregulation of the three genes analyzed (Figure 4). These observations are consistent with the elevated levels of PSMA, TERT, and PDEF at the protein level and suggest that both transcriptional and posttranscriptional mechanisms are involved in the upregulation of PSMA, TERT, and PDEF in malignant tumors of the prostate.

Discussion

Prostatic tumors are the most common malignant tumors in males and the second cause of male cancer deaths⁴. Because of prostatic tumors have become an important health issue as the male population continues to age⁵. Un-

fortunately, the molecular mechanisms leading to the prostatic tumor and the development to malignant phenotype are mostly unknown. The uncertain disease course, as well as the heterogeneity of the disease, hinders the research to better understand the occurrence of prostatic tumor. Also, this situation complicates the research with clinical specimens or studies on the progression of the prostatic tumor over a certain period⁷⁻⁹. In recent years, the incidence of prostatic diseases has increased continuously, and their progression to malignant tumors makes them a serious health concern¹⁰. Older males represent the largest population of prostatic tumors, which are usually accompanied by symptoms like hematuria and dysuria¹¹. The diagnosis of prostatic tumor mainly depends on imaging, prostatic biopsy, and the pathological examination of specimens obtained during surgery¹²⁻¹⁴. In recent years, most studies showed that PSMA, TERT, and PDEF play important roles in the development of prostatic tumors. PSMA, TERT, and PDEF are expressed at low levels in normal tissues, but are upregulated in tumors, including prostatic tumor^{15,16}. PSMA can serve as a therapeutic target for the immunotherapy of dendritic cells, and the overexpression of PSMA gene can also be used as the cytotoxic reagent mediated into the prostatic tumor cells¹⁷. Normal cells transfected with TERT can be immortalized without any transformation in the phenotype of nuclei. TERT can maintain the length of telomeres and is believed to be




Figure 3. Expression of PSMA, TERT and PDEF protein in the malignant tumor of the prostatic tissues and normal tissues.




Figure 4. mRNA expression of PSMA, TERT and PDEF in the malignant tumor of the prostatic tissues and normal

associated with the aging process and tumors. The TERT expression can only be detected in cells with telomerase activity, but cannot be detected in most benign tissues¹⁸. TERT can endow immortality to cells, which is a key step in the transformation of malignant tumors. Thus, infiltrated tumor cells can be detected with high sensitivity using TERT from benign tissues. The role of PDEF is very important in hematopoiesis, angiogenesis, myogenesis and neural connection¹⁹. Normal differentiation of epithelial cells in the prostate and the initial stages of the prostatic tumor are dependent on the testosterone, but the final stage of prostatic tumor becomes almost hormone independent and resistant to hormone therapies.

Conclusion

Our study showed high expression of PSMA, TERT and PDEF in the prostatic malignant tumor, suggesting the important roles of PSMA, TERT, and PDEF in the development of the malignant tumor of the prostate. Therefore, PSMA, TERT and PDEF can serve as potential targets for the treatment of malignant tumor of the prostate and as the new reference for clinical diagnosis and prognosis.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) KWAK JT, HONG CW, PINTO PA, WILLIAMS KRUECKER J. Is visual registration equivalent to semiautomated registration in prostate biopsy? *Biomed Res Int* 2015; 2015: 39-42.
- 2) FELDMAN BJ, FELDMAN D. The development of androgen-independent prostate cancer. *Nat Rev Cancer* 2001; 1: 34-45.
- 3) WU W, LIU X, CHAFTARI M, LERUZ CARRERAS MI, GONZALEZ C, VILLALBA UPCHURCH J, MERRIMAN SM, DALAL S, YEUNG J. Association of body composition with outcome in docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. *PLoS One* 2015; 10: e0122002.
- 4) HAYWARD SW, CUNHA GR. The prostate: development and histology. *Radiol Clin North Am* 2000; 38: 21-37.
- 5) HAYWARD SW, BASKIN AS, LAUGHNEY PC, FOSTER ΣBA, GONZALEZ AR, DAHIYA R, CUNHA GR. Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. *Acta Anat (Basel)* 1996; 155: 94-103.
- 6) WANG Y, HAYWARD SW, CAO M, THAYER K, CUNHA G. Cell differentiation stage in the prostate. *Differentiation* 2001; 68: 100e9.
- 7) COSTA FILIPE L, COSTA VL, RIBEIRO FR, MARTINS AT, TEIXEIRA MR. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. *Apoptosis* 2010; 15: 966-965.
- 8) ABATE-SHEN C, SHEN MM. Molecular genetics of prostate cancer. *Genes Dev* 2000; 14: 2410e34.
- 9) TSUJIMURA A, KOIKAWA Y, SALM S, TAKAO T, COETZEE S, MOSCATELLI D, SHAPIRO E, LEPOR H, SUN TT, WILSON EL. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. *J Cell Biol* 2002; 157: 1257-1265.
- 10) CHOI N, ZHANG B, ZHANG L, ITTMANN M, XIN L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. *Cancer Cell* 2012; 21: 253-265.
- 11) TAYLOR BS, SCHULTZ N, HIERONYMUS H, GOPALAN A, XIAO Y, CARVER BS, ARORA VK, KAUSHIK P, CERAMI E, REVA B, ANTIPIN Y, MITSIADES N, LANDERS T, DOLGALEV I, MAJOR JE, WILSON M, SOCCI ND, LASH AE, HEGUY A, EASTHAM JA, SCHER HI, REUTER VE, SCARDINO PT, SANDER C, SAWYERS CL, GERALD WL. Integrative genomic profiling of human prostate cancer. *Cancer Cell* 2010; 18: 11-22.
- 12) MA X, ZIEL-VAN DER MADE AC, AUTAR B, VAN DER KORPUT HA, VERMEIJ M, VAN DUJIN P, CLEUTJENS KB, DE KRUGER R, KRIMPENFORT P, BERNIS A, VAN DER KWAST TH, TRAPMAN J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. *Cancer Res* 2005; 65: 5730-5739.
- 13) LEONG KG, GAO WO. The Notch pathway in prostate development and cancer. *Differentiation* 2008; 76: 699-716.

- 14) VAN LEENDERS GJ, SCHALKEN JA. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. *Crit Rev Oncol Hematol* 2003; 46 (Suppl): S3-10.
- 15) VERHAGEN PC, VAN DUJIN PW, HERMANS KG, LOOIJENGA LH, VAN GURP RJ, STOOP H, VAN DER KWAST TH, TRAPMAN J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. *J Pathol* 2006; 208: 699-707.
- 16) FERREIRA R, OHNEDA KAND, YAMAMOTO M. GATA1 function, a paradigm for transcription factors in hematopoiesis. *Mol Cell Biol* 2005; 25: 1215-1227.
- 17) COKIC VP, SMITH RD, BELESLIN-COKIC BB. Hydroxyurea induces fetal hemoglobin by the nitricoxide-dependent activation of soluble guanylylcyclase. *J Clin Invest* 2003; 111: 231-239.
- 18) DAVIES JH, EVANS BA, JENNEY ME. Effects of chemotherapeutic agents on the function of primary human osteoblast-like cells derived from bone marrow. *Clin Endocrinol Metab* 2003; 88: 607-609.
- 19) RHIM JS. In vitro human cell culture models for the study of prostate cancer. *Prostate Cancer Prostatic Dis* 2000; 3: 229-235.
- 20) KARAN D, SCHMIED BM, DAVE BJ, SHEN Y, CHEN J, LIN MF, BATRA SK. Decreased androgen responsiveness and growth of human prostate cancer is associated with increased gene alterations. *Clin Cancer Res* 2001; 7: 3472-3480.
- 21) ALBERTI C. Prostate cancer: both microRNA aberrant expression-mediated autophagy and radiation therapy resistance mechanisms show cross-reference to epigenetic/genetic mechanisms: implications for drug development. *J Med Pharmacol Sci* 2016; 20: 1001-1012.